Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Dynamics of circulating monomeric C-reactive protein (mCRP) to predict outcomes with first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Anniken Joerlo Fuglestad, Paula A. Bousquet, Lawrence A. Potempa et al. Jun 01, 2026 pp. 3606-3606 10.1200/jco.2026.44.16_suppl.3606

3606 Background: Elevated CRP levels at CRC diagnosis are consistently associated with poor outcomes, suggesting a tumor-p...

Clinicopathological characteristics and survival outcomes of liver cancer in a tertiary oncology center.

Emmanuel Temitope Andero, Anthonia Sowunmi, Muhammad Yaqub Habeebu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16187

e16187 Background: Liver cancer is an aggressive malignancy with poor overall survival, particularly when diagnosed at adv...

Geographic access to ONC201 (dordaviprone) trials for pediatric diffuse midline glioma in the United States: County travel burden and social vulnerability gradients.

Jay Shah, Alaa Mahmoud, Khaled M. El-Husseiny Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14054

e14054 Background: ONC201 (dordaviprone) is currently under study for H3 K27M–mutant midline gliomas including pediatric d...

Real-world outcomes and recurrence risk factors of liver transplantation for permanently unresectable colorectal liver metastases following the TransMet trial.

Rene Adam, Jean Emmanuel Langdorph, Céline Piedvache et al. Jun 01, 2026 pp. 3589-3589 10.1200/jco.2026.44.16_suppl.3589

3589 Background: Following the TRANSMET trial that demonstrated an overall survival (OS) benefit of liver transplantation...

Efficacy and safety of XNW27011, a Claudin-18.2 targeted (CLDN18.2) ADC, in advanced pancreatic ductal adenocarcinoma: A phase 2 study.

Linlin Wang, Tianshu Liu, Zeng-Qing Guo et al. Jun 01, 2026 pp. 3039-3039 10.1200/jco.2026.44.16_suppl.3039

3039 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a historically poor prognosis, t...

PFS2 outcomes by prior therapy from DREAMM-8: A phase 3 study assessing belantamab mafodotin (belamaf), pomalidomide, and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Guldane Cengiz Seval, Sosana Delimpasi, Vladimir I. Vorobyev et al. Jun 01, 2026 pp. 7566-7566 10.1200/jco.2026.44.16_suppl.7566

7566 Background: B-cell maturation antigen (BCMA)–directed therapies have transformed the treatment landscape in RRMM. Bel...

Single-cell analysis and functional profiling of galectin-3 in the tumor immune microenvironment in transformed follicular lymphoma.

Xiaohui Wang, Huilai Zhang Jun 01, 2026 pp. 7055-7055 10.1200/jco.2026.44.16_suppl.7055

7055 Background: Histological transformation of follicular lymphoma (tFL) represents an aggressive subtype characterized b...

Clinical utility of DNA and RNA next-generation sequencing (NGS) for accurate diagnosis (Dx) and sub-classification of bone and soft tissue tumors (BST).

Rachel B. Keller-Evans, Steven Christopher Smith, Erik A. Williams et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23521

e23521 Background: BST account for only 1-2% of adult cancers but encompass >100 distinct entities with diverse histolo...

Efficacy and safety analysis of intraoperative radiotherapy for soft tissue sarcoma: The largest-sample, single-center, real-world data review.

Zhichao Liao, Jilong Yang Jun 01, 2026 pp. 11579-11579 10.1200/jco.2026.44.16_suppl.11579

11579 Background: This study aimed to evaluate the efficacy and safety of surgery combined with intraoperative radiotherap...

Outcomes of inpatient (IP) systemic cancer therapy in patients (pts) with solid tumors.

Max Duesberg, Margaret Shyu, Jason Yu-Shen Chang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23059

e23059 Background: Administration of IP cancer therapy requires substantial resources and carries risk of toxicity. Given...

Impact of DLL3 expression and tumor subtype on response to tarlatamab.

Jessica Ross, Jake June-Koo Lee, Sarah Cascarino et al. Jun 01, 2026 pp. 8087-8087 10.1200/jco.2026.44.16_suppl.8087

8087 Background: Tarlatamab is a DLL3-targeted bispecific T-cell engager used to treat small cell lung cancer (SCLC). SCLC...

Atrial fibrillation as a sentinel cardiovascular event in renal cell carcinoma hospitalizations: National Inpatient outcomes and rescue failure (NIS 2016–2023).

Zin Thandar Win, Ramaditya Srinivasmurthy, Rishi Kumar Nanda et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23226

e23226 Background: Cardiovascular instability is common during renal cell carcinoma (RCC) hospitalizations, yet atrial fib...

The impact of language barriers on financial toxicity for Spanish-speaking patients undergoing cancer treatment.

Alejandra Felix, Matthew P. Banegas, Gabriela Lopez Ruano Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13504

e13504 Background: Financial toxicity refers to the economic burden experienced by patients due to medical care costs. Can...

Single-cell spatial analysis of the tumor immune microenvironment in NSCLC primary tumors and brain metastases.

Lauren Julia Brown, Jordan W. Conway, Angela L. Ferguson et al. Jun 01, 2026 pp. 8585-8585 10.1200/jco.2026.44.16_suppl.8585

8585 Background: Brain metastases (BrM) are associated with poor prognosis in non-small cell lung cancer (NSCLC). Although...

Operational and clinical drivers of subcutaneous PD-1/PD-L1 inhibitor adoption: A mixed-methods analysis of U.S. oncology practice patterns.

Kimberly Peihsi Ku, Sarah Hendry, Olivia Parry Jun 01, 2026 pp. 1550-1550 10.1200/jco.2026.44.16_suppl.1550

1550 Background: Subcutaneous (SC) formulations of PD-1/PD-L1 inhibitors have recently been approved across multiple solid...

Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: Updated results from the phase Ib BEACON study.

Jia Fan, Jian Zhou, Xiao-Wu Huang et al. Jun 01, 2026 pp. 2508-2508 10.1200/jco.2026.44.16_suppl.2508

2508 Background: Advanced hepatocellular carcinoma (HCC) remains a high unmet-medical-need malignancy with limited therape...

ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.

Toni K. Choueiri, Piotr Tomczak, Naomi Balzer Haas et al. Jun 01, 2026 pp. 4502-4502 10.1200/jco.2026.44.16_suppl.4502

4502 Background: In the phase 3 KEYNOTE-564 trial (NCT03142334), adjuvant pembrolizumab (pembro) was superior to placebo (...

Safety and efficacy of full-dose apixaban vs rivaroxaban for cancer-associated venous thromboembolism in patients with solid tumors: A real-world study.

Salih Akgun, Kofi Boakye Opoku, Ahmed Demirci et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23439

e23439 Background: Cancer-associated venous thromboembolism (CA-VTE) is a major cause of morbidity and mortality in patien...

Enhanced recovery after surgery in major oncologic head and neck surgery: A systematic review and meta-regression.

Ali Moinuddin, Maisara Morshed, Fatimah Bemat et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13616

e13616 Background: Major oncologic head and neck surgery (OHN) is associated with complex hospitalization and perioperativ...

Real-world clinical utility of liquid biopsy in NSCLC in a community oncology practice: Concordance, discordance, and impact on precision therapy.

Salman J. Khan, Hamza Usman, Seemab Sheikh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15068

e15068 Background: Precision oncology in NSCLC relies on tissue NGS to identify actionable mutations, but in community onc...

Feasibility of a novel oncologist-led diagnostic algorithm for Lynch syndrome in colorectal cancer patients: The ItaLynch study.

Alberto Puccini, Eva Blondeaux, Francesca Bergamo et al. Jun 01, 2026 pp. 10618-10618 10.1200/jco.2026.44.16_suppl.10618

10618 Background: International guidelines recommend universal Lynch syndrome (LS) screening in colorectal cancer (CRC) us...

Helicobacter pylori infection, systemic inflammation, and colorectal cancer: A prospectively enrolled case–control study.

Saad Manzoor, Mounika Kotte, Abdul Ghani Iqbal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15668

e15668 Background: The association between Helicobacter pylori (H. pylori) infection and colorectal cancer (CRC) remains c...

TAGNOT: A phase 1b/2 tumor-agnostic study of the selective anti-FGFR1 monoclonal antibody OM-RCA-01 in FGFR1-expressing advanced solid tumors.

Igor A. Utyashev, Svetlana Kutukova, Grigory A. Raskin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3166

TPS3166 Background: Fibroblast growth factor receptor 1 (FGFR1) plays a key role in the pathogenesis of multiple malignanc...

Prospective real time clinical validation of a novel circulating tumor–derived blood mRNA Geneverify test for diagnosis of breast cancer.

Sudhir K. Rawal, Smreti Vasudevan, Samson Mani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15053

e15053 Background: Early detection is critical for the effective management of breast cancer. We performed a real-time cli...

Mitochondrial apoptosis markers in the progression of endometrioid adenocarcinoma.

Elena A. Ozerkova, Elena M. Frantsiyants, Irina V. Kaplieva et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17625

e17625 Background: Endometrial cancer (EC) is one of the most common malignancies of the female reproductive system. The i...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page